ተጨማሪ መረጃ ― አማርኛ

Keratoacanthoma (KA) በፈጣን እድገት እና በራሱ ወደ ኋላ የመመለስ አቅም ያለው ተደጋጊ የቆዳ እጢ ነው። ብዙውን ጊዜ በፀሐይ ላይ የተጎዳቸው፣ ዕድሜ የገፉና ፍትሃዊ ቆዳ ያላቸው ወንዶች ላይ ነው። ኤክሴሽን ወይም ሞህስ ማይክሮግራፊካል ቀዶ ጥገናን በመጠቀም የተለመደው ሕክምና ቢሆንም፣ ሌሎች የተለያዩ የሕክምና አማራጮች አሉ።
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.

Keratoacanthoma (KA) ዝቅተኛ ደረጃ ያለው እጢ ሲሆን፣ በቆዳው ውስጥ ያሉትን የተወሰኑ እጢዎች ላይ ይጀምራል፣ እና በአጉሊ መነጽር ከ squamous cell carcinoma (SCC) ጋር ይመሳሰላል። KA እንደ ወራሪ SCC አይነት መተው አለበት ብሎ የተነሳ ቀጣይነት ያለው ክርክር አለ።
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.

Cutaneous squamous cell carcinoma (cSCC) በሰዎች ላይ, በተለይም በዕድሜ የገፉ ግለሰቦች ላይ, ሁለተኛው በጣም የተለመደ የካንሰር አይነት ነው። ቀዶ ጥገና በተለምዶ cSCCን ለማከም ጥቅም ላይ ይውላል፣ ነገር ግን ቀዶ ጥገና ማድረግ የማይችሉ ወይም ለማይፈልጉ ታካሚዎች እንደ ውስጠ-ቁስ ህክምና ያሉ ሌሎች አማራጮች ሊወሰዱ ይችላሉ። ባህላዊ የውስጥ ሕክምናዎች (methotrexate or 5-fluorouracil) ጥቅም ላይ ውለዋል፣ ነገር ግን intralesional immunotherapy እና oncolytic virotherapy ያሉ አዳዲስ አቀራረቦች ላይ ቀጣይነት ያለው ምርምር አለ። እዚህ ላይ፣ ከጥንታዊ ዘዴዎች ጀምሮ እስከ መጨረሻው ጫፍ ስልቶች ድረስ, የተለያዩ intralesional ሕክምናዎችን ለcSCC እንመለከታለን።
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.